Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Buy" from Brokerages

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has been given a consensus rating of "Buy" by the nine brokerages that are currently covering the company, MarketBeat reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $15.72.

A number of analysts recently weighed in on the stock. Canaccord Genuity Group reissued a "buy" rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Wedbush reissued an "outperform" rating and issued a $9.00 target price (down previously from $11.00) on shares of Voyager Therapeutics in a research note on Tuesday, February 11th. StockNews.com cut shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, December 13th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Monday. Finally, Cantor Fitzgerald initiated coverage on shares of Voyager Therapeutics in a research note on Friday, January 10th. They set an "overweight" rating and a $5.73 price objective on the stock.

Insider Transactions at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the transaction, the chief operating officer now directly owns 112,328 shares in the company, valued at $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have sold 10,778 shares of company stock worth $58,548. Corporate insiders own 4.53% of the company's stock.

Hedge Funds Weigh In On Voyager Therapeutics

Several large investors have recently bought and sold shares of VYGR. Empowered Funds LLC lifted its holdings in Voyager Therapeutics by 5.4% in the third quarter. Empowered Funds LLC now owns 44,809 shares of the company's stock valued at $262,000 after buying an additional 2,278 shares during the period. Intech Investment Management LLC acquired a new position in Voyager Therapeutics in the third quarter valued at approximately $74,000. Massachusetts Financial Services Co. MA lifted its holdings in Voyager Therapeutics by 19.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 171,856 shares of the company's stock valued at $1,005,000 after buying an additional 28,333 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Voyager Therapeutics by 2.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company's stock valued at $804,000 after buying an additional 3,473 shares during the period. Finally, FMR LLC lifted its holdings in Voyager Therapeutics by 26.9% in the third quarter. FMR LLC now owns 92,498 shares of the company's stock valued at $541,000 after buying an additional 19,622 shares during the period. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Trading Down 4.2 %

NASDAQ VYGR traded down $0.17 on Friday, reaching $3.91. The company's stock had a trading volume of 383,912 shares, compared to its average volume of 362,550. The firm has a market cap of $213.59 million, a PE ratio of 5.51 and a beta of 0.91. The business has a 50-day moving average price of $5.18 and a 200 day moving average price of $6.00. Voyager Therapeutics has a 52 week low of $3.88 and a 52 week high of $10.66.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.